Dicerna Pharma (DRNA) Misses Q4 EPS by 7c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Dicerna Pharmaceuticals (DRNA) PT Lowered to $22 at H.C. Wainwright
March 12, 2019 8:07 AM EDTH.C. Wainwright analyst Ed Arce lowered the price target on Dicerna Pharmaceuticals (NASDAQ: DRNA) to $22.00 (from $24.00) while maintaining a Buy rating. Dicerna remains on track to initiate PHYOX2, its pivotal, multidose, double-blind, placebo-controlled trial of lead compound DCRPHXC later this month. Yesterday, on... More
